Maryland-based pharmaceutical company Novavax Inc. announced June 14 its recombinant nanoparticle protein-based COVID-19 vaccine reached its primary endpoint in its Phase 3 trial.
The vaccine demonstrated 90.4 percent efficacy and 100 percent protection against moderate and severe disease. Notably, the vaccine demonstrated 93.2 percent efficacy against variants of interest and variants of concern of SARS-CoV-2, the virus that causes COVID-19.
The protein-based vaccine candidate, NVX-CoV2373, is engineered from the genetic sequence of the first strain of SARS-CoV-2. The vaccine uses recombinant nanoparticle technology to generate antigens from the coronavirus spike protein.
Novavax plans to apply for emergency use authorization from the Food and Drug Administration in the third quarter of 2021. The company has pledged to manufacture 100 million doses per month by the end of the third quarter and 150 million doses per month by the end of the fourth quarter of 2021.
CDC Urges Vaccine Allocation to Hospitals
The Centers for Disease Control and Prevention (CDC) asked health care jurisdictions to distribute a portion of their existing COVID-19 vaccine allocation to hospitals, emergency departments, and urgent care facilities to vaccinate patients at discharge.
To increase health equity in COVID-19 vaccination, the agency urges health care jurisdictions to prioritize facilities in counties with a high Social Vulnerability Index ranking, as well as disproportionate share hospitals, hospitals in the Health Resources and Services Administration Small Rural Hospital Improvement Program, and hospitals that serve a large number of people who have no other routine source of care.
CDC has released a fact sheet with more information about training and enrolling as a COVID-19 vaccination provider.
Visit the America’s Essential Hospitals coronavirus resource page for more information about the pandemic.
Contact Senior Director of Policy Erin O’Malley at firstname.lastname@example.org or 202.585.0127 with questions.